Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation." ...

LONDON, Aug 13 (Reuters) - Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart ...

Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported on ...

Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales, ...

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis(NOVN.S), opens new tab said on Monday it had agreed to pay up to $1.5 ‌billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to ...

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Cognizant secures a five-year AI-driven IT operations deal with Novartis to enhance efficiency and technology integration.

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...

Novartis beat second-quarter profit forecasts and kept its 2026 outlook unchanged on Tuesday, ‌saying one-off benefits that helped the quarter would reverse as it increases research and launch ...

Natco Pharma has approached the Delhi High Court, contesting the Indian Patent Office's decision to grant Novartis a second ...

The private equity firm has taken control of the BSE-listed drugmaker, appointed Vikas Gupta as CEO and plans to build a branded generics platform in India ...